BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220706
DTEND;VALUE=DATE:20220708
DTSTAMP:20260516T022139
CREATED:20220126T093554Z
LAST-MODIFIED:20220303T093817Z
UID:32980-1657065600-1657238399@www.pharmajournalist.com
SUMMARY:Microbiome Connect: Europe
DESCRIPTION:The 8th Annual Microbiome Connect: Europe 2022 dedicated to showcasing the leading drug development and consumer product platforms applying live microbial consortia\, engineered microbes\, and microbial-derived metabolites for therapeutic and health applications in patients and consumers. \nAs the first EMA approved microbiome-targeted therapeutics emerge on the horizon\, drug developers will have to opportunity to benchmark their rational drug platforms\, targeting validated pathways in gastrointestinal\, neurological\, metabolic disorders\, as well as oncology-based indications. \nFurthermore\, there will be separate tracks dedicated to developing novel\, clinical-validated product formulations for nutritional\, digestive wellness\, oral and skincare applications. \nJoin the microbiome field to hear from biotechs\, pharma voices\, investment bodies\, consumer product brands and more\, on how to develop robust\, scalable\, and reproducible formulations for microbe-derived/-targeting products entering late-stage investigations and reaching for the market. \nTo know more visit: https://hubs.ly/Q012R7H40
URL:https://www.pharmajournalist.com/event/microbiome-connect-europe/
LOCATION:Amsterdam
ORGANIZER;CN="Kisaco Research":MAILTO:Jessica.Mockler@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220711
DTEND;VALUE=DATE:20220714
DTSTAMP:20260516T022139
CREATED:20220330T093536Z
LAST-MODIFIED:20220623T094708Z
UID:33675-1657497600-1657756799@www.pharmajournalist.com
SUMMARY:3rd Annual Gene Therapy for Neurological Disorders Europe
DESCRIPTION:Accelerating Europe’s Progress in CNS Gene Therapy \nNavigating Europe-Specific Challenges & European Regulators Requirements; Optimizing Preclinical Research in Neurological Models & Revolutionizing Gene Therapy Delivery to CNS Targets in the Clinic \nAs programs advance globally\, the 3rd Annual Gene Therapy for Neurological Disorders Europe meeting is the industry’s definitive forum dedicated to showcasing the European landscape’s progress and specific regulatory challenges as they move from rare neurological disorders to targeting more common diseases including Parkinson’s\, epilepsy and neurodevelopmental disorders. \nReturning as its first in-person meeting\, with brand new speakers and companies joining the conversation\, attend alongside 100 fellow preclinical\, translational\, clinical and commercial gene therapy experts to overcome your translational challenges and improve the delivery of your gene therapy to its CNS target\, and optimize your European strategy as you move from rare to common patient populations. \nTo know more visit: https://ter.li/l4b1t3
URL:https://www.pharmajournalist.com/event/3rd-annual-gene-therapy-for-neurological-disorders-europe/
LOCATION:Paris Marriott Charles de Gaulle Airport Hotel\, Zone Hoteliere\, 5 All. du Verger\, Roissy-en-France\, 95700
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220711
DTEND;VALUE=DATE:20220714
DTSTAMP:20260516T022139
CREATED:20220412T094733Z
LAST-MODIFIED:20220412T094733Z
UID:33773-1657497600-1657756799@www.pharmajournalist.com
SUMMARY:Digital Biomarkers and Clinical Measures in Neurology Summit
DESCRIPTION:The Digital Biomarkers & Clinical Measures in Neurology Summit is the definitive industry forum sharing cross-industry insight to transform clinical development with digital data. \nFrom integrating wearable technologies\, smartphone apps\, and speech-based digital biomarkers into remote clinical research to elucidating pathways to clinical validation to establish therapeutic efficacy\, join industry experts from Merck\, Janssen\, GSK\, Sanofi\, Novartis\, Takeda\, Eli Lilly & Company\, Mitsubishi Tanabe Pharma Holdings America and many more to improve patient retention and establish efficacy with richer datasets. \nTo know more visit: https://ter.li/mk4lmh
URL:https://www.pharmajournalist.com/event/digital-biomarkers-and-clinical-measures-in-neurology-summit/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220712
DTEND;VALUE=DATE:20220715
DTSTAMP:20260516T022139
CREATED:20220413T082618Z
LAST-MODIFIED:20220413T085216Z
UID:33780-1657584000-1657843199@www.pharmajournalist.com
SUMMARY:3rd GxP Cloud Compliance Summit
DESCRIPTION:Migrate Your GxP Regulated Applications to the Cloud with Compliance\, Security\, & Quality Assurance  \nWith hot anticipation for the FDA’s new CSA guidance\, life science companies have the opportunity to take a proactive stance in their approach to the new methodologies. In the climate of this exciting new era of computer systems validation\, join over 100 Life Science\, IT & Quality professionals at the 3rd GxP Cloud Compliance Summit. \nEmulating on 2021’s success\, the 3rd GxP Cloud Compliance Summit is excited to return in July\, for the first time in person! \nThis is your only opportunity to develop and implement a practical roadmap to migrate your GxP regulated applications to the cloud with real-life insights from regulatory\, security and quality experts from leading life science companies\, as well as cloud providers\, auditors\, and industry regulators. \nWith the FDA strongly advising life science organizations to start getting ready for CSA now\, join us in July to discover how your business can get ahead and simplify the transition process. \nTo know more visit: https://ter.li/uichgz
URL:https://www.pharmajournalist.com/event/3rd-gxp-cloud-compliance-summit/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220712
DTEND;VALUE=DATE:20220715
DTSTAMP:20260516T022139
CREATED:20220427T072259Z
LAST-MODIFIED:20220427T072259Z
UID:33913-1657584000-1657843199@www.pharmajournalist.com
SUMMARY:BCMA Targeted Therapies Summit
DESCRIPTION:With the undeniable excitement in the BCMA field over the past few months\, the BCMA-Targeted Therapies Summit returns to the space to equip you with the knowledge and connections to revolutionize your BCMA-centered pipeline. \nPick the brains of 90+ academic and industry pioneers at the first physical edition of the only meeting dedicated to supercharging transformative next generation BCMA-targeted therapies into the clinic\, navigating the complex landscape and optimizing clinical strategy to revolutionize treatment of multiple myeloma and beyond. \nHear from leading speakers including: \n\n\n\nSuzette Girgis\, Senior Director & Head of Clinical Pharmacology & Hematologic Malignancies\, Johnson & Johnson Services\nEric Fedyk\, Global Program Leader of BCMA Assets\, 2seventy bio\nDavid DiLillo\, Director\, Immuno-Oncology\, Regeneron\nBrandon Kremer\, Group Senior Medical Director\, Clinical Development Lead\, GlaxoSmithKline\nNathan Martin\, Translational Scientist & Project Lead\, Bristol Myers Squibb\nMike Damore\, Director & Lead – Translational Oncology\, Pfizer\nChetasi Talati\, Medical Director\, AbbVie\nDexiu Bu\, Senior Principle Scientist\, CART group\, Immuno-Oncology & Hematology\, Novartis\nFaiza Zafar\, Senior Medical Science Liaison\, Legend Biotech\n\n\n\nTake a look at the full event guide to learn more.
URL:https://www.pharmajournalist.com/event/bcma-targeted-therapies-summit/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220713
DTEND;VALUE=DATE:20220715
DTSTAMP:20260516T022139
CREATED:20220323T103153Z
LAST-MODIFIED:20220324T101902Z
UID:33612-1657670400-1657843199@www.pharmajournalist.com
SUMMARY:Advanced Wound Care Summit
DESCRIPTION:The Advanced Wound Care Innovation Summit is the first industry-led forum focused on delivering innovative wound care treatments to patients. Expect to hear from\, and discuss with\, world leaders of wound care research who are driving the development of novel biomaterials\, remote-monitoring devices\, and digital health management solutions. \nFind out how C-level Executives\, VPs and Directors of R&D are tackling the most pressing industry challenges and seizing new growth opportunities. Whether an executive\, investor\, researcher or healthcare professional\, this meeting offers an empowering environment that allows you to make wound care decisions with confidence. \nTo know more visit: www.advancedwoundcareusa.com
URL:https://www.pharmajournalist.com/event/advanced-wound-care-summit/
LOCATION:Boston\, MA (Venue TBD)
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220715
DTEND;VALUE=DATE:20220717
DTSTAMP:20260516T022139
CREATED:20220126T093119Z
LAST-MODIFIED:20220126T093119Z
UID:32975-1657843200-1658015999@www.pharmajournalist.com
SUMMARY:RNA Therapeutic Modalities Summit USA
DESCRIPTION:The RNA Therapeutic Modalities Summit is North America’s only industry led conference covering clinical progress and commercial scale development for the full spectrum of RNA therapeutic approaches. \nOur agenda will featuring the pioneering biotechs translating current vaccine success into further clinically validated treatments in broader indications using RNA technologies such as antisense oligonucleotides\, aptamers\, small interfering RNAs (siRNAs)\, microRNAs\, and messenger RNA (mRNA). \nThere will be dedicated discussion on the rationale for different mechanisms-of-action\, how to optimise the power and versatility of RNA-based constructs\, and the progress to date in disease indications encompassing neurodegeneration\, metabolic and cardiovascular disorders and various cancers. \nIf your R&D teams are looking to establish a differentiated drug platform through RNA modification and delivery systems\, improve stability\, delivery and durability of current drug candidates\, or enable tissue-specific administration with higher targeting ability and less toxicity\, make sure they secure a place at this hotly anticipated conference. We look forward to welcoming you to Boston for dedicated in-person networking in June! \nTo know more visit: https://hubs.ly/Q012R75G0
URL:https://www.pharmajournalist.com/event/rna-therapeutic-modalities-summit-usa/
LOCATION:Boston\, USA
ORGANIZER;CN="Kisaco Research":MAILTO:Jessica.mockler@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220718
DTEND;VALUE=DATE:20220721
DTSTAMP:20260516T022139
CREATED:20220304T093223Z
LAST-MODIFIED:20220621T095620Z
UID:33445-1658102400-1658361599@www.pharmajournalist.com
SUMMARY:2nd Annual Next Generation Gene Therapy Vectors Summit
DESCRIPTION:Overcome First Generation Gene Therapy Vector Challenges To Guarantee Targeted\, Specific\, Efficient & Safe Gene Delivery \nThe 2nd Next Generation Gene Therapy Vectors Summit is dedicated to overcoming the current immunogenicity\, toxicity and manufacturability challenges facing the field by pioneering the next generation of superior delivery vectors to deliver safe and efficacious gene therapy products. \nIndustry pioneers from cutting edge biopharma and world-leading academic vectorology groups are set to share clinically meaningful insights on how to enhance existing vectors and pioneer radical novel approaches to deliver genes more efficiently and safely. \nSpanning a range of delivery approaches from cutting-edge AAV capsid optimization\, utilizing lenti and other viral vectors\, to innovative non-viral gene therapy approaches\, this comprehensive event will enable you to reduce immunogenicity\, improve tissue targeting\, simplify manufacturing and enhance the safety profile of your approach. \nEverything in gene therapy starts with delivery\, so join this definitive\, niche conference to delve into the details of vector design\, engineering and optimization case studies\, equipping you with the insights required to deliver transformative therapeutics to patients more effectively and safely than ever before. \nTo know more visit: https://ter.li/3mccj3
URL:https://www.pharmajournalist.com/event/2nd-annual-next-generation-gene-therapy-vectors-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220718
DTEND;VALUE=DATE:20220721
DTSTAMP:20260516T022139
CREATED:20220613T095312Z
LAST-MODIFIED:20220613T095312Z
UID:34412-1658102400-1658361599@www.pharmajournalist.com
SUMMARY:LEAP HR Life Sciences East
DESCRIPTION:LEAP HR: Life Sciences East 2022 Conference will be taking place as an in-person event in Boston\, July 18-20. Returning as a physical event for its seventh year\, this event will showcase 35+ case studies of how life sciences organizations of all stages and sizes are redefining post-pandemic best practices and turbocharging the employee experience to meet the holistic and previously unmet needs of your in-demand life science workforce. \nThis is a unique chance to take advantage of a combination of plenary sessions\, breakout sessions\, panels and roundtable discussions specifically designed to solve your biggest HR challenges and deliver actionable insights for HR innovation. \nNetwork with 250+ other strategic HR leaders working within life sciences on the East Coast and surrounding areas and join a support network of 500+ life science HR leaders who have previously taken part. \nYou’ll hear from companies such as: Takeda\, Novo Nordisk\, AstraZeneca\, Pfizer\, Alexion Pharmaceuticals\, Regeneron Pharmaceuticals\, Alnylam Pharmaceuticals\, BioNTech\, Ipsen\, Novartis\, PTC Therapeutics\, TCR2 Therapeutics\, Ginkgo BioWorks and more… \nFind out more by visiting the website: https://leap-hr-lifesciences-east.com/
URL:https://www.pharmajournalist.com/event/leap-hr-life-sciences-east/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220725
DTEND;VALUE=DATE:20220728
DTSTAMP:20260516T022139
CREATED:20220526T184152Z
LAST-MODIFIED:20220526T184152Z
UID:34241-1658707200-1658966399@www.pharmajournalist.com
SUMMARY:Cell Therapy Potency Assay Summit
DESCRIPTION:Cell Therapy Potency Assay Summit\, taking place from 25-27 of July in Boston\, will bring together professionals working in analytical development\, quality\, regulatory and process development functions. \nJoin your peers to: \n\nBrainstorm best-in-class approaches to overcome variability in QC\nCompare next gen approaches from cytotoxicity to omics\nDevelop reference standards to benchmark across the industry\nCreate an assay with commercialization in mind.\n\nThis summit will equip you with the tools you need to fast track your regulatory submissions and ease through clinical development. \nYou can view the event guide here: https://ter.li/6a13vg \nSecure your place at the summit here: https://ter.li/zp17ep \nWe are looking forward to welcoming you to Boston this July!
URL:https://www.pharmajournalist.com/event/cell-therapy-potency-assay-summit/
LOCATION:The Bostonion\, 26 North Street\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220726
DTEND;VALUE=DATE:20220729
DTSTAMP:20260516T022139
CREATED:20220407T101301Z
LAST-MODIFIED:20220413T091417Z
UID:33748-1658793600-1659052799@www.pharmajournalist.com
SUMMARY:3rd Gamma Delta T Therapies Summit
DESCRIPTION:The data has dropped and 2022 has been touted as a monumental year for γδT Therapies \nWith Adicet Bio\, In8Bio\, Gamma Delta Therapeutics\, Lava Therapeutics\, and ImCheck Therapeutics releasing clinical data from engineered and antibody-based γδT Therapy in patients; the race to market for the first allogeneic and solid tumor-targeting γδT Therapy is truly on. \nJoin the 3rd Gamma Delta T Therapies Summit to learn and network with 120+ of the world’s leaders including γδT pioneer\, Adrian Hayday\, and together accelerate the development of effective\, persistent\, globally accessible cell therapy for solid tumors. \nTake a look at the official program here. \nEnhance cytotoxicity\, discover novel targets\, engineer stealth and persistence\, interrogate cell subsets\, and scale-up manufacturing through a deep understanding of the fundamental biology and target product profile for γδT therapies. \nIndustry experts agree that this year\, the γδT is the cell to know. Ensure you and your team are ahead of the curve and equipped with the need-to-know insights to advance successful therapeutics\, across 2 dedicated tracks covering Discovery\, Process Research\, Preclinical\, and Clinical Development; as well as 3 deep-dive workshops\, and a Gamma Delta 101 Bootcamp.
URL:https://www.pharmajournalist.com/event/3rd-gamma-delta-t-therapies-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220726
DTEND;VALUE=DATE:20220729
DTSTAMP:20260516T022139
CREATED:20220407T101551Z
LAST-MODIFIED:20220413T091500Z
UID:33751-1658793600-1659052799@www.pharmajournalist.com
SUMMARY:3rd Annual B & T Cell-Mediated Autoimmune Disease Drug Development Summit
DESCRIPTION:The 3rd Annual B & T Cell-Mediated Autoimmune Disease Drug Development Summit is the only industry-led forum focused on the therapeutic opportunity of drugs directed against B-cell\, plasma cell\, and T-cell targets in autoimmunity. \n \nSeveral drug approvals for B-cell directed therapies have made waves in autoimmune drug development. As investment and industry momentum increases\, this summit will once again unite the movers and shakers of the B&T cell-mediated autoimmune space with the likes of Pfizer\, Nurix\, Regeneron\, Gossamer Bio\, and more. \nTake a look at the 2022 program here. \nAttending this summit is a unique opportunity to be involved in interactive discussions on: \n\nOvercoming challenges of heterogeneity of disease models and demonstrating B cell activation in tissues\nEmerging therapies including B-cell specific therapies\, tolerizing approaches\, small molecule drugs\, engineered cell immunotherapy\, B&T cell checkpoint targeting\, FcRn inhibition\, as well as PROTAC/degrader approaches\nTherapeutic opportunities across both peripheral and tissue specific autoimmune diseases\nOvercoming clinical challenges of treating B&T cell mediated autoimmune diseases through combinatorial regimens that target T-cell co-stimulation\, leveraging autoantibody signatures to identify patient responders and discussing autoimmune disease biomarkers\n\nAs the space grapples with translational and early clinical drug development challenges\, join this comprehensive forum 80+ key leaders and decision-makers to harness the immune system and conquer B&T cell mediated autoimmune diseases.
URL:https://www.pharmajournalist.com/event/3rd-annual-b-t-cell-mediated-autoimmune-disease-drug-development-summit/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220726
DTEND;VALUE=DATE:20220730
DTSTAMP:20260516T022139
CREATED:20220425T085640Z
LAST-MODIFIED:20220425T085640Z
UID:33898-1658793600-1659139199@www.pharmajournalist.com
SUMMARY:Cytokine-Based Drug Development Summit
DESCRIPTION:The 3rd Cytokine-Based Drug Development Summit has been developed following extensive research to address YOUR biggest challenges in the cytokine field. \nWith 30+ expert speakers\, including the hottest academic researchers and leading figures from the industry\, this 4-day program is your opportunity to gain insight into the latest clinical advancement and have thought provoking discussions around how to overcome the fields greatest drug development challenges. \nWhat can you expect to see? \n\nFurther your understanding of the underlying mechanisms of action\, and T-cell exclusion from the tumor in order to turn cold tumors ‘hot’ with Ask-Gene Pharma\nOptimize cytokine engineering to ensure stability and improve the favorable risk benefit profile with Proviva Therapeutics\nLeverage insights from industry’s leading lights to overcome toxicity challenges by ensuring tumor targeting is selective and therefore enhances the anti-tumor response with Equilium\, Cytonus Therapeutics & Cytimmune\nTake a deep dive into preclinical cancer models covering both in vitro and in-vivo studies and how these are unveiling the most favoured pharmaceuticals properties of therapeutic cytokines with Astra Zeneca & Xilio Therapeutics\nUncover the latest data coming out of the clinic of cytokines in combination with checkpoint inhibitors and monoclonal antibodies with Alkermes & NeoImmune Tech\n\nGet your copy of the brand-new agenda for the full list of speakers and sessions.
URL:https://www.pharmajournalist.com/event/cytokine-based-drug-development-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220726
DTEND;VALUE=DATE:20220729
DTSTAMP:20260516T022139
CREATED:20220509T102858Z
LAST-MODIFIED:20220509T102858Z
UID:34021-1658793600-1659052799@www.pharmajournalist.com
SUMMARY:2nd Annual mRNA-Based Therapeutics Summit
DESCRIPTION:Do you want to be part of the largest gathering of mRNA professionals? \nThe 2nd Annual mRNA-Based Therapeutics Summit is returning in-person to Boston this July 26-28. \nExpect exclusive data from the movers and shakers in mRNA vaccine and therapy development\, 75+ world-class speakers\, 5 dedicated tracks of content and 45+ deep-dive case studies. Find out more in the full event guide: https://ter.li/yc800m \nHere’s a snapshot of the expert speakers you can hear from: \n\n​​​​Kathy Fernando\, VP\, Head of Worldwide Research\, Development and Medical Operations & Head of mRNA Scientific Planning\, Pfizer\nRegis Gervier\, Global Head\, mRNA Center of Excellence\, Sanofi\nRituparna Das\, VP – COVID Vaccines\, Moderna\nHao Chen\, Global Head of Cell & Viral Drug Substance\, GlaxoSmithKline\nJoe Payne\, Founder\, President & CEO\, Arcturus Therapeutics\nPervin Anklesaria\, Deputy Director\, HIV Vaccines & Biologics\, Bill & Melinda Gates Foundation\nManmohan Singh\, SVP – Pharmaceutical Sciences & Delivery Technologies\, Beam Therapeutics\nAkhilesh Bhambhani\, Senior Director – Biologics Drug Product Development; Tech Dev/Tech Ops\, Ultragenyx\nLiang Shang\, Senior Scientist – Vaccine Analytical\, Merck\nRussell Johnson\, VP – Formulation Research\, RVAC Medicines\nTamar Grossman\, Global Head – RNA & Targeted Therapeutics\, The Janssen Pharmaceutical Companies of Johnson & Johnson\n\nDownload the official brochure to discover why Sanofi\, Ultragenyx\, Beam Therapeutics\, Pfizer\, Moderna\, Merck\, Eli Lilly\, GSK\, and 300+ others have already secured their places.  https://ter.li/yc800m
URL:https://www.pharmajournalist.com/event/2nd-annual-mrna-based-therapeutics-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220726
DTEND;VALUE=DATE:20220729
DTSTAMP:20260516T022139
CREATED:20220518T092848Z
LAST-MODIFIED:20220518T092848Z
UID:34131-1658793600-1659052799@www.pharmajournalist.com
SUMMARY:iPSC Manufacturing Summit
DESCRIPTION:With iPSCs exhibiting game-changing potential in the bid to develop an off-the-shelf therapy\, the brand-new iPSC Manufacturing Summit is the only summit dedicated to solving the manufacturing\, quality and analytical challenges hindering your iPSC-derived treatments from reaching patients. \nThis forum will unite the exclusive community advancing the production of high-quality and consistent iPSC products\, with in depth case studies aimed to develop optimal differentiation\, cryopreservation\, and analytical protocol to enhance process development to ensure it is robust\, rapid and repeatable. \nOur 17+ expert speakers will be addressing methods to enhance potency testing and cell characterization\, enhance iPSC product quality\, and integrate successful gene-editing into your manufacturing. \nTake a look at the full event guide to learn more.
URL:https://www.pharmajournalist.com/event/ipsc-manufacturing-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220726
DTEND;VALUE=DATE:20220729
DTSTAMP:20260516T022139
CREATED:20220526T182248Z
LAST-MODIFIED:20220526T182344Z
UID:34229-1658793600-1659052799@www.pharmajournalist.com
SUMMARY:Targeted Radiopharmaceuticals Summit US (TRP US)
DESCRIPTION:The brand-new Targeted Radiopharmaceuticals Summit US (TRP US) is the only industry-led meeting dedicated to developing next-generation radioligands. The TRP sector has developed dramatically over the previous 18 months\, with a wave of new investment in light of Lutathera’s extraordinary performance. \nAre you part of a pharmaceutical business aiming to have their Theranostic approved? If so\, this agenda is designed to deliver you a well-rounded and complete understanding of the fast-paced radiopharmaceutical sector while also learning about the critical function of diagnostic imaging. \nHear the latest insights\, case studies\, and novel data to help accelerate the development of next-generation radioligand therapies from clinical approval to commercialization. This is the only in-person meeting to bring the discussion around the challenges and opportunities facing developers of Theranostic radioligand therapies. \nTo know more visit: https://ter.li/jtzz4q
URL:https://www.pharmajournalist.com/event/targeted-radiopharmaceuticals-summit-us-trp-us/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR